Cargando…
Immune checkpoint inhibitors further aggravate proteinuria in patients with metastatic renal cell carcinoma after long-term targeted therapy
BACKGROUND: Increasing number of patients with metastatic renal cell carcinoma (mRCC) are receiving subsequent programmed cell death protein-1 (PD-1) inhibitor combination therapy following tyrosine-kinase inhibitor (TKI) resistance. To explore whether PD-1 inhibitor would further deteriorate protei...
Autores principales: | Ning, Kang, Wu, Zeshen, Zou, Xiangpeng, Liu, Huiming, Wu, Yi, Xiong, Longbin, Yu, Chunping, Guo, Shengjie, Han, Hui, Zhou, Fangjian, Dong, Pei, Zhang, Zhiling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984970/ https://www.ncbi.nlm.nih.gov/pubmed/35402197 http://dx.doi.org/10.21037/tau-21-1015 |
Ejemplares similares
-
Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma
por: Zhang, Zhiling, et al.
Publicado: (2021) -
Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy
por: Ning, Kang, et al.
Publicado: (2022) -
Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
por: Wu, Zeshen, et al.
Publicado: (2022) -
Nkx2.8 promotes chemosensitivity in bladder urothelial carcinoma via transcriptional repression of MDR1
por: Zhou, Zhaohui, et al.
Publicado: (2022) -
Long-term effect of acute ischemic injury on the kidney underwent clamped partial nephrectomy
por: Zhou, Zhaohui, et al.
Publicado: (2023)